Rigel Pharmaceuticals (Rigel Pharmaceuticals (RIGL)) stock is trading sharply higher Tuesday after the company signed an exclusive global licensing agreement with Arvinas (Arvinas (ARVN)) and Pfizer (Pfizer (PFE)) for VEPPANU (vepdegestrant), an oral PROTAC drug designed to treat certain types of breast cancer. The news comes on a rough day for the broader market — the S&P 500 is down about 1% — but the healthcare sector is bucking the trend, up 2.39% and making it the best-performing sector today.
So what exactly is VEPPANU? It's part of a new class of drugs called PROTACs, which stands for proteolysis-targeting chimeras. Instead of just inhibiting a disease-causing protein, these molecules hijack the body's natural protein disposal system to degrade the target protein entirely. Think of it like calling in a wrecking crew instead of just locking the door.
The drug recently scored a big win: In May 2026, the FDA approved VEPPANU for patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer. The approval was based on the Phase 3 VERITAC-2 trial, which showed that VEPPANU reduced the risk of disease progression or death by 43% compared to fulvestrant, a standard endocrine therapy. Median progression-free survival was 5.0 months in the VEPPANU arm versus 2.1 months in the fulvestrant arm. Overall survival data is still early — only 16% of patients had died at the time of the analysis — but the efficacy signal is clear.
Under the terms of the deal, Rigel will contribute up to $40 million toward VEPPANU's development over the next four years. In return, the company gets the right to launch the drug in the U.S. and can pursue global rights, which could open up a significant revenue stream. For a company of Rigel's size, this is a potentially transformative opportunity.
As of publication, Rigel shares were up 10.69% at $29.00, according to market data. The market is clearly betting that VEPPANU has legs — and with a novel mechanism of action and a recent FDA approval, that bet might just pay off.
